Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Iodine-resistant Thyroid Cancer”

6 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 6 results

Testing effectiveness (Phase 2)Study completedNCT01286753
What this trial is testing

Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation

Who this might be right for
Neoplasms
Hoffmann-La Roche 51
Very early researchLooking for participantsNCT06632860
What this trial is testing

A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors

Who this might be right for
Iodine-resistant Thyroid CancerMeningiomaNETs
Peking Union Medical College Hospital 40
Testing effectiveness (Phase 2)Study completedNCT01013597
What this trial is testing

Trial of LBH589 in Metastatic Thyroid Cancer

Who this might be right for
Thyroid Carcinoma
University of Wisconsin, Madison 13
Testing effectiveness (Phase 2)Study completedNCT05745363
What this trial is testing

Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 33
Not applicableStudy completedNCT04821336
What this trial is testing

Cholesterol Metabolites Analysis in Human Thyroid and Iodine Resistance

Who this might be right for
Thyroid Cancer
Institut Claudius Regaud 30
Testing effectiveness (Phase 2)Looking for participantsNCT07092514
What this trial is testing

Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

Who this might be right for
Thyroid CancerCancer of the Thyroid
Washington University School of Medicine 34